Protagonist Therapeutics (PTGX) Change in Acquisitions & Divestments (2016 - 2026)

Protagonist Therapeutics has disclosed Change in Acquisitions & Divestments across 11 years of filings, most recently posting $3.4 million for Q1 2026.

• Change in Acquisitions & Divestments for Q1 2026 came in at $3.4 million, down 51.66% year-over-year; the trailing twelve-month figure through Mar 2026 was $488.2 million (up 88.8% YoY), and the FY2025 annual result was $491.8 million, up 52.0% from the prior year.
• Change in Acquisitions & Divestments came in at $3.4 million for Q1 2026 at Protagonist Therapeutics, down from $484.8 million in the prior quarter.
• In the past five years, Change in Acquisitions & Divestments ranged from a high of $484.8 million in Q4 2025 to a low of $3.4 million in Q1 2026.
• The 5-year median for Change in Acquisitions & Divestments is $58.7 million (2024), against an average of $85.2 million.
• Peak annual rise in Change in Acquisitions & Divestments reached 357.42% in 2025, while the deepest fall reached 90.28% in 2025.
• Protagonist Therapeutics' Change in Acquisitions & Divestments stood at $84.6 million in 2022, then plunged by 56.62% to $36.7 million in 2023, then soared by 188.81% to $106.0 million in 2024, then surged by 357.42% to $484.8 million in 2025, then plunged by 99.3% to $3.4 million in 2026.
• The last three Change in Acquisitions & Divestments figures came in at $3.4 million (Q1 2026), $484.8 million (Q4 2025), and $7.0 million (Q1 2025), per Business Quant data.